The global systemic lupus erythematous (SLE) drugs market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Systemic Lupus Erythematous (SLE) is a chronic autoimmune disease that causes the immune system to attack healthy body tissue. In SLE, the body immune system can affect any part of the body, such as joints, organs, eyes, skin, among others. The major factor for the growth of the market during the forecast period is the high prevalence of autoimmune diseases, particularly systemic lupus erythematous (SLE).

According to the Lupus Foundation of America, 1.5 million Americans, and at least five million people have a form of lupus globally. Additionally, lupus strikes mostly women of childbearing age. However, men, children, and teenagers can also develop lupus. Further, as per the same source, almost 90% of people living with lupus are women and most people develop the disease between the ages of 15-44. Apart from this, there are 16,000 new cases of lupus every year.

Some major key players in the market include Bristol-Myers Squibb Co., GlaxoSmithKline plc, and Sanofi S.A., among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in December 2020, GlaxoSmithKline plc received approval for BENLYSTA (belimumab) by the FDA for the treatment of adult patients with active lupus nephritis. Lupus nephritis is a serious inflammation of the kidneys caused by systemic lupus erythematosus (SLE).

Market Coverage

• The market number available for – 2020-2027

• Base year- 2020

• Forecast period- 2021-2027

• Segment Covered- 

o By Product 

o By Distribution Channel

• Regions Covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

• Competitive Landscape-Bristol-Myers Squibb Co., GlaxoSmithKline plc,and Sanofi S.A., among others.

Key questions addressed by the report

• What is the market growth rate?

• Which segment and region dominate the market in the base year?

• Which segment and region will project the fastest growth in the market?

• How has COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

• Who is the leader in the market?

• How players are addressing challenges to sustain growth?

• Where is the investment opportunity?

Global Systemic Lupus Erythematous (SLE) Drugs Market Report by Segment

By Product

• Corticosteroids

• Non-Steroidal Anti-inflammatory Drugs (NSAIDs)

• Anti-Inflammatories

• Disease-Modifying Anti-Rheumatic Drugs (DMARDs)

• Antimalarials

• BLyS-specific Inhibitors or Monoclonal Antibodies (MAbS)

• Immunosuppressive Agents/Immune Modulators

• Anticoagulants

By Distribution Channel 

• Hospital Pharmacies

• Drug Stores

• Online Drug Stores

Global Systemic Lupus Erythematous (SLE) Drugs Market Report by Region

North America

• United States

• Canada

Europe

• UK

• Germany

• Italy

• Spain

• France

• Rest of Europe 

Asia-Pacific

• China

• India

• Japan

• South Korea

• Rest of Asia-Pacific 

Rest of the World

• Latin America 

• Middle East & Africa